Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06568939

A Phase 2, Open-Label, Randomized Study of Three Telisotuzumab Vedotin Doses in Adults With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced or Metastatic Non-Squamous NSCLC

Led by AbbVie · Updated on 2026-06-05

150

Participants Needed

72

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Non-small cell lung cancer (NSCLC) is a condition where cancer cells grow uncontrollably in lung tissues. This trial evaluates the safety and effects of telisotuzumab vedotin, an investigational drug, in adults with NSCLC that overexpresses c-Met. The study focuses on changes in disease activity and treatment side effects in participants previously treated for this cancer type. Participants will be randomly assigned to one of three groups, each receiving a different dose of telisotuzumab vedotin through intravenous infusion. The study lasts about three years, during which participants receive the assigned dose regularly. The trial is open-label and conducted globally, involving approximately 150 adults who have specific tumor characteristics and prior treatment history. During the trial, participants will visit hospitals or clinics regularly for medical assessments, blood tests, and side effect monitoring. Researchers will measure safety through adverse event tracking, including lung disease, nerve problems, and eye disorders. They will also assess the drug's presence in the blood and patient-reported outcomes over the study period. The trial aims to understand the drug's safety, how it moves through the body, and its impact on cancer progression and overall survival.

CONDITIONS

Brief Title

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Projected life expectancy of at least 12 weeks
  • Diagnosed with c-Met overexpressing non-small cell lung cancer (NSCLC) confirmed by specific lab testing
  • Histologically or cytologically documented NSCLC that is locally advanced or metastatic
  • Known EGFR activating mutation status
  • Measurable disease based on RECIST version 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
  • Received no more than 1 line of prior systemic cytotoxic chemotherapy for advanced or metastatic NSCLC
  • Progressed on at least 1 prior therapy for locally advanced or metastatic NSCLC
Not Eligible

You will not qualify if you...

  • Adenosquamous, neuroendocrine histology, or sarcomatoid features
  • Presence of EGFR activating mutations such as Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations
  • Prior treatment with c-Met-targeted antibodies, telisotuzumab vedotin, or related antibody-drug conjugates
  • Prior docetaxel therapy
  • Metastases to the central nervous system unless adequately treated
  • History of other cancers not allowed by protocol
  • History or evidence of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or active pneumonitis on screening CT scan
  • Unresolved significant adverse events from prior cancer therapy except alopecia or anemia
  • Major surgery within 21 days before randomization
  • Clinically significant conditions as detailed in the protocol
  • Significant liver disease including hepatitis, alcohol abuse, or cirrhosis
  • Grade 2 or higher edema, lymphedema, ascites, or pleural effusion
  • Grade 2 or higher neuropathy
  • Active uncontrolled bacterial or viral infection
  • Active corneal disorder

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to approximately 3 years

Participants receive intravenous infusions of telisotuzumab vedotin at one of three dose levels.

Regular visits for drug infusions and assessments during treatment

Trial Site Locations

Total: 72 locations

1

Ironwood Cancer and Research Center /ID# 276370

Chandler, Arizona, United States, 85224

Actively Recruiting

2

University of Arkansas for Medical Sciences /ID# 272923

Little Rock, Arkansas, United States, 72205

Actively Recruiting

3

Valkyrie Clinical Trials /ID# 271322

Los Angeles, California, United States, 90067

Actively Recruiting

4

Yale New Haven Hospital /ID# 271584

New Haven, Connecticut, United States, 06510

Actively Recruiting

5

Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899

Jacksonville, Florida, United States, 32256

Actively Recruiting

6

Ocala Oncology Center /ID# 273697

Ocala, Florida, United States, 34474

Actively Recruiting

7

Memorial Hospital West /ID# 270313

Pembroke Pines, Florida, United States, 33028

Actively Recruiting

8

Comprehensive Hematology Oncology /ID# 270422

St. Petersburg, Florida, United States, 33701-4732

Actively Recruiting

9

Florida Cancer Specialists - North /ID# 271995

St. Petersburg, Florida, United States, 33705

Actively Recruiting

10

Florida Cancer Specialists - East /ID# 271993

West Palm Beach, Florida, United States, 33401

Actively Recruiting

11

University Cancer & Blood Center /ID# 270969

Athens, Georgia, United States, 30607

Actively Recruiting

12

Northwest Georgia Oncology Centers /ID# 275374

Marietta, Georgia, United States, 30060

Actively Recruiting

13

Memorial University Medical Center /ID# 272467

Savannah, Georgia, United States, 31404

Actively Recruiting

14

Kaiser Permanente Moanalua Medical Center /ID# 272916

Honolulu, Hawaii, United States, 96819

Actively Recruiting

15

University of Illinois Hospital and Health Sciences System /ID# 275345

Chicago, Illinois, United States, 60607

Actively Recruiting

16

Illinois Cancer Specialists /ID# 274678

Niles, Illinois, United States, 60714

Actively Recruiting

17

Springfield Clinic - First /ID# 272576

Springfield, Illinois, United States, 62702

Actively Recruiting

18

NHO - Nebraska Hematology-Oncology /ID# 272970

Lincoln, Nebraska, United States, 68506

Actively Recruiting

19

Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527

Omaha, Nebraska, United States, 68130

Actively Recruiting

20

Renown Regional Medical Center /ID# 273535

Reno, Nevada, United States, 89502

Actively Recruiting

21

Astera Cancer Care /ID# 272359

East Brunswick, New Jersey, United States, 08816-4096

Actively Recruiting

22

Regional Cancer Care Associates /ID# 270783

Teaneck, New Jersey, United States, 07666

Actively Recruiting

23

Montefiore Medical Center - Einstein Campus /ID# 277169

The Bronx, New York, United States, 10461

Actively Recruiting

24

Clinical Research Alliance - Westbury /ID# 270455

Westbury, New York, United States, 11590

Actively Recruiting

25

FirstHealth of the Carolinas- Speciality Center /ID# 272924

Pinehurst, North Carolina, United States, 28374

Actively Recruiting

26

Mercy Health - Perrysburg Cancer Center /ID# 270536

Perrysburg, Ohio, United States, 43551

Actively Recruiting

27

Genesis Healthcare System /ID# 273361

Zanesville, Ohio, United States, 43701

Actively Recruiting

28

Guthrie Robert Packer Hospital /ID# 270316

Sayre, Pennsylvania, United States, 18840

Actively Recruiting

29

Cancer Care Associates Of York /ID# 270971

York, Pennsylvania, United States, 17403

Actively Recruiting

30

Medical University of South Carolina /ID# 273272

Charleston, South Carolina, United States, 29425

Actively Recruiting

31

Saint Francis Cancer Center - Greenville /ID# 276368

Greenville, South Carolina, United States, 29607

Actively Recruiting

32

SCRI Oncology Partners /ID# 270162

Nashville, Tennessee, United States, 37203

Actively Recruiting

33

Texas Oncology - Dallas - Worth Street /ID# 278947

Dallas, Texas, United States, 75246

Actively Recruiting

34

Texas Oncology - Northeast Texas /ID# 272000

Tyler, Texas, United States, 75702

Actively Recruiting

35

Community Cancer Trials Of Utah /ID# 276598

Ogden, Utah, United States, 84405

Actively Recruiting

36

Virginia Cancer Specialists - Fairfax /ID# 272004

Fairfax, Virginia, United States, 22031

Actively Recruiting

37

Medical Oncology Associates - Spokane /ID# 277172

Spokane, Washington, United States, 99208

Actively Recruiting

38

Northwest Medical Specialties Tacoma /ID# 270534

Tacoma, Washington, United States, 98405

Actively Recruiting

39

Hospital De Câncer De Pernambuco /ID# 276104

Recife, Pernambuco, Brazil, 50040-000

Actively Recruiting

40

Liga Norte Riograndense Contra O Cancer /ID# 273183

Natal, Rio Grande do Norte, Brazil, 59075-740

Actively Recruiting

41

ONCOSITE - Centro de Pesquisa Clinica em Oncologia /ID# 272513

Ijuí, Rio Grande do Sul, Brazil, 98700-000

Actively Recruiting

42

Beijing Chest Tumor Hospital /ID# 271935

Beijing, Beijing Municipality, China, 101149

Actively Recruiting

43

Fujian Province Cancer Hospital /ID# 276178

Fuzhou, Fujian, China, 350014

Actively Recruiting

44

Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931

Nanning, Guangxi, China, 530021

Actively Recruiting

45

Henan Cancer Hospital /ID# 271927

Zhengzhou, Henan, China, 450008

Actively Recruiting

46

Union Hospital - Tongji Medical College /ID# 271668

Wuhan, Hubei, China, 430022

Actively Recruiting

47

The First Affiliated Hospital of Nanchang University /ID# 271666

Nanchang, Jiangxi, China, 330006

Actively Recruiting

48

The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928

Xi'an, Shaanxi, China, 710061

Actively Recruiting

49

LinYi Cancer Hospital /ID# 272068

Linyi, Shandong, China, 276001

Actively Recruiting

50

Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933

Ürümqi, Xinjiang, China, 830011

Actively Recruiting

51

Meir Medical Center /ID# 270071

Kefar Sava, Central District, Israel, 4428164

Actively Recruiting

52

Rabin Medical Center. /ID# 270087

Petah Tikva, Central District, Israel, 4941492

Actively Recruiting

53

Rambam Health Care Campus- Haifa /ID# 270078

Haifa, Israel, 3109601

Actively Recruiting

54

Shaare Zedek Medical Center /ID# 270095

Jerusalem, Israel, 9103102

Completed

55

Nagoya University Hospital /ID# 277010

Nagoya, Aichi-ken, Japan, 466-8560

Actively Recruiting

56

Hokkaido University Hospital /ID# 277014

Sapporo, Hokkaido, Japan, 060-8648

Actively Recruiting

57

Kobe Minimally Invasive Cancer Center /ID# 277469

Kobe, Hyōgo, Japan, 650-0046

Actively Recruiting

58

Kitasato University Hospital /ID# 277012

Sagamihara-shi, Kanagawa, Japan, 252-0375

Actively Recruiting

59

Sendai Kousei Hospital /ID# 277023

Sendai, Miyagi, Japan, 981-0914

Actively Recruiting

60

University of Miyazaki Hospital /ID# 277020

Miyazaki, Miyazaki, Japan, 889-1692

Actively Recruiting

61

Kurashiki Central Hospital /ID# 276995

Kurashiki-shi, Okayama-ken, Japan, 710-8602

Actively Recruiting

62

Fujieda Municipal General Hospital /ID# 277025

Fujieda, Shizuoka, Japan, 426-0077

Actively Recruiting

63

Wakayama Medical University Hospital /ID# 276997

Wakayama, Wakayama, Japan, 641-8510

Actively Recruiting

64

Institute for Oncology and Radiology of Serbia /ID# 270561

Belgrade, Beograd, Serbia, 11000

Actively Recruiting

65

Military Medical Academy /ID# 279873

Belgrade, Beograd, Serbia, 11000

Actively Recruiting

66

University Clinical Center Serbia /ID# 270808

Belgrade, Beograd, Serbia, 11000

Actively Recruiting

67

Clinical Hospital Center - Bežanijska Kosa /ID# 270558

Belgrade, Beograd, Serbia, 11080

Actively Recruiting

68

University Clinical Center Nis /ID# 270557

Niš, Nisavski Okrug, Serbia, 18300

Actively Recruiting

69

Institute For Pulmonary Diseases Of Vojvodina /ID# 270559

Kamenitz, Sremski Okrug, Serbia, 21208

Actively Recruiting

70

University Clinical Center Kragujevac /ID# 275773

Kragujevac, Sumadijski Okrug, Serbia, 34000

Actively Recruiting

71

National Cancer Centre Singapore /ID# 271499

Singapore, Central Singapore, Singapore, 169611

Actively Recruiting

72

National University Hospital /ID# 271700

Singapore, Singapore, 119074

Actively Recruiting

Loading map...

Research Team

A

ABBVIE CALL CENTER

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Similar Trials

Preoperative 3-D Virtual Resection Predicts Lung Function Af...

Non-small Cell Lung Cancer

Actively Recruiting

1 location

68Ga-grazytracer PET/CT for Early Assessment of Response to ...

Non-Small Cell Lung Cancer

Actively Recruiting

1 location

A Phase 3 Study of MK-1084 with Subcutaneous Pembrolizumab a...

Non-small Cell Lung Cancer

Actively Recruiting

175 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here